查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1324371

2030 年炎症性腸病治療市場預測 - 按類型、藥物類別、給藥途徑、配銷通路和地區進行的全球分析

Inflammatory Bowel Disease Treatment Market Forecasts to 2030 - Global Analysis By Type (Ulcerative Colitis and Crohn's Disease), Drug Class, Route of Administration, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3個工作天內

價格

據Stratistics MRC預測，2023年全球炎症性腸病治療市場規模將達到214.7億美元，預計在預測期內將以5.6%的年複合成長率成長，到2030年達到314.4億美元。

術語炎症性腸病（IBD）是指潰瘍性大腸炎和克隆氏症，這兩種胃腸道慢性炎症的疾病。消化器官系統因炎症而遭受長期損害。治療大腸激躁症的目標是減少引起症狀和體徵的炎症。在最好的情況下，它可以緩解症狀、長期緩解並降低合併的風險。 IBD 的治療通常涉及藥物治療或手術。

據 ClinicalTrials.gov. 稱，在 2,784 項與 IBD 相關的臨床試驗（包括藥物開發、觀察性研究等）中，目前僅在美國就進行了 965 項。

市場動態：

患病率上升意味著更多患者接受治療

許多要素導致潰瘍性大腸炎和克隆氏症的患病率不斷增加，包括遺傳傾向、環境觸發因素和免疫系統疾病。大多數罹患潰瘍性大腸炎或克隆氏症患者都有家族病史。許多政府機構正在通過教育公眾了解這些疾病的症狀、診斷和治療來提高公眾對這些疾病的認知。因此，新興國家消費者對各種治療的認知不斷提高，疾病診斷率不斷提高，預計將推動市場擴張。

高成本

在開發中國家，由於缺乏對炎症性腸病的了解，導致接受治療的人數減少。此外，高昂的治療成本，包括藥物和其他成本，預計將限制炎症性腸病治療在患者中的使用。此外，生物製劑擴大用於治療潰瘍性大腸炎和克隆氏症，但生物製劑治療的高成本限制了市場的擴張。

由於強大的管道分子組合，產品推出量增加

推動炎症性腸病治療市場成長的要素包括克隆氏症和潰瘍性大腸炎患病率的上升以及全球範圍內認知的提高。因此，許多重要的行業公司正在專注於研發，以探索新的有前景的 IBD 治療候選藥物。

新藥研發有限和技術挑戰

正在開發的治療 IBD 的新藥數量很少，而且大多數都專注於類似的作用機制。因此，製藥行業將很難區分其藥品，這可能導致價格上漲。 IBD市場涉及許多法律，包括有關臨床試驗、附加檔和安全監測的法律。對於製藥公司來說，遵守這些法規既耗時又昂貴。

COVID-19 的影響：

由於COVID-19的影響，炎症性腸病治療市場在預測期內擴張更為緩慢。世界各地診斷設施的關閉、旅行限制和封鎖是導致這種疾病治療速度緩慢的一些因素。 2020年產生的收入明顯低於2019年。

克隆氏症預計將在預測期內成為最大的部分

在預測期內，克隆氏症預計將佔最大佔有率。克隆氏症患罹患率的上升以及國際上接受克隆氏症治療的人數都被認為推動了該市場的擴張。例如，據 Deutsches Arztblatt 報導，德國每 10 萬人中有 100 至 200 名克隆氏症患者。

預計注射劑領域在預測期內的年複合成長率最高。

由於生物製劑產品核可的增加以及生物製劑在潰瘍性大腸炎和克隆氏症治療中的使用增加，預計注射劑領域在預測期內將表現出最高的年複合成長率。例如，艾伯維 (AbbVie) 於 2021 年 2 月宣布 FDA 批准修美樂 (Humira) 用於治療年輕患者中度至重度活動性潰瘍性大腸炎。 Humira 通過皮下注射給藥。因此，用於治療 IBD 的生物製劑的需求不斷成長，支持了注射劑行業的擴張。

佔比最高的地區

北美在全球炎症性腸病治療市場的主導地位是由於存在大量強大的市場參與者及其眾多的戰略舉措。此外，該地區改進的報銷做法、更高的治療率以及增加創新療法的處方正在支持該地區的擴張。持續努力發現創新療法和政府支持措施預計也將推動該地區的擴張。

複合年複合成長率最高的地區：

預計亞太地區將在預測期內實現最高成長。未來幾年推動市場擴張的關鍵原因包括人口高齡化、炎症性疾病市場發展的巨大潛力、炎症性腸病患病率的增加以及該地區健康狀況的改善，例如護理政策。此外，該地區主要企業的投資增加以及生物學名藥和生物製劑的接受度不斷提高，預計將在不久的將來支持市場擴張。

免費客製化服務：

訂閱此報告的客戶將收到以下免費客製化選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（注：基於可行性檢查）
  • 競爭標杆管理
    • 根據產品系列、地域分佈和戰略聯盟對主要企業進行基準測試

目錄

第1章 執行摘要

第2章 前言

  • 執行摘要
  • 利益相關者
  • 調查範圍
  • 調查方法
    • 資料挖掘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 新興市場
  • COVID-19 的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球炎症性腸病治療市場：按類型

  • 潰瘍性大腸炎
  • 克隆氏症

第6章 全球炎症性腸病治療市場：按藥物類別

  • JAK抑製劑
  • 抗整合素藥物
  • IL抑製劑
  • 腫瘤壞死因子抑製劑
  • 皮質類固醇
  • 氨基水楊酸鹽
  • 按其他藥物類別

第7章 炎症性腸病治療的全球市場：按給藥途徑

  • 注射
  • 口服劑

第8章 全球炎症性腸病治療市場：按配銷通路分類

  • 網上藥房
  • 零售藥房
  • 醫院藥房

第9章 全球炎症性腸病治療市場：按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第10章 進展

  • 契約、夥伴關係、聯盟和合資企業
  • 收購和合併
  • 新產品上市
  • 業務擴展
  • 其他關鍵策略

第11章公司簡介

  • Allergan plc.
  • Janssen Biotech
  • Celltrion Inc.
  • Pfizer Inc
  • Merck & co., inc
  • Bristol-myers squibb company
  • Bausch health companies inc
  • Takeda Pharmaceutical Company Limited
  • Novartis AG
  • UCB SA
  • Amgen Inc
  • Johnson & Johnson Services, Inc
  • Biogen
  • AbbVie Inc.,
Product Code: SMRC23596

According to Stratistics MRC, the Global Inflammatory Bowel Disease Treatment Market is accounted for $21.47 billion in 2023 and is expected to reach $31.44 billion by 2030 growing at a CAGR of 5.6% during the forecast period. The term "inflammatory bowel disease" (IBD) is used to describe ulcerative colitis and Crohn's disease, two conditions in which the GI tract is chronically inflamed. The digestive system becomes damaged over time by inflammation. The goal of treating irritable bowel syndrome is to reduce the inflammation that is the source of your signs and symptoms. In the best-case scenario, this might lead to symptom relief, a long-term remission, and lowered complications risks. For the treatment of IBD, drugs or surgery are usually employed.

According to ClinicalTrials.gov., there are currently 965 clinical trials being undertaken in the United States alone out of the 2,784 clinical trials (including medication development, observational studies, and others) connected to IBD.

Market Dynamics:

Driver:

Increasing prevalence of disease is presenting a large patient pool undergoing treatment

Many factors, including genetic predisposition, environmental triggers, and immune system disturbances, are responsible for the rising prevalence of ulcerative colitis and Crohn's disease. The majority of individuals who have ulcerative colitis or Crohn's disease have a family history of the condition. By educating the public about these diseases' symptoms, diagnoses, and treatments, a number of government agencies are raising public awareness of these illnesses. Therefore, it is projected that growing consumer awareness of various treatment alternatives and rising disease diagnosis rates in developing nations will boost market expansion.

Restraint:

High cost

In underdeveloped nations, there is a lack of knowledge regarding inflammatory bowel disease, which lowers the number of individuals receiving treatment. Additionally, it is anticipated that high treatment costs, including those associated with drugs and other expenses, may restrict the use of an inflammatory bowel disease treatment among patients. Additionally, biologics are being used more frequently to treat ulcerative colitis and Crohn's disease, but the market expansion is being constrained by the high costs of biologic treatment.

Opportunity:

Strong portfolio of pipeline molecules to increase product launches

Some of the reasons driving the growth of the inflammatory bowel disease treatment market include the rising prevalence of Crohn's disease and ulcerative colitis, as well as increased awareness of the condition on a global scale. As a result, a number of important industry firms are concentrating on R&D and looking into new prospective candidates for the treatment of IBD.

Threat:

Limited pipeline of new drugs and technical challenges

The number of new medications being developed to treat IBD is rather small, and most of them focus on similar mechanisms of action. The pharmaceutical industry may find it harder to differentiate its medicines as a result, which may put pressure on prices. A number of laws, including those governing clinical trials, labeling, and safety monitoring, pertain to the IBD market. For pharmaceutical companies, complying with these rules can be time- and money-consuming.

COVID-19 Impact:

The market for treating inflammatory bowel disease expanded more slowly during the predicted period as a result of COVID-19's effects. The closure of diagnostic facilities, travel restrictions, and lockdowns in numerous nations worldwide are a few of the causes contributing to the disease's delayed rate of treatment. The revenue generated in 2020 was significantly lower than it was in 2019.

The crohn's disease segment is expected to be the largest during the forecast period

The Crohn's disease segment is expected to hold the largest share during the forecast period. The rising incidence of Crohn's disease and the number of people undergoing treatment for it internationally are both credited with driving the expansion of this market. For instance, according to the Deutsches Arztblatt, there are 100 to 200 cases of Crohn's disease per 100,000 people in Germany.

The injectables segment is expected to have the highest CAGR during the forecast period

Due to rising product approvals for biologics as well as rising biologic usage for the treatment of ulcerative colitis and Crohn's disease, the injectables sector is anticipated to have the highest CAGR over the projection period. For instance, AbbVie Inc. announced in February 2021 that the FDA had approved HUMIRA for the treatment of moderate to severe active ulcerative colitis in juvenile patients. Through subcutaneous injections, HUMIRA is administered. Thus, the expansion of the injectables sector is supported by the rising demand for biologics for the treatment of IBD.

Region with largest share:

North America dominated the global market for the treatment of inflammatory bowel disease as a result of the existence of numerous powerful market players and the numerous strategic initiatives they carried out there. Additionally, the region's improved reimbursement practices, high treatment rates, and rising prescription of innovative treatments are aiding regional expansion. The region's expansion is also predicted to be fueled by continuous efforts to discover innovative therapies and supportive government initiatives.

Region with highest CAGR:

Over the forecast period, Asia-Pacific is expected to experience the highest growth. Some of the key reasons driving market expansion in the upcoming years include an aging population, a high chance of developing inflammatory diseases, an increase in the prevalence of inflammatory bowel diseases, and better healthcare policies in the area. Additionally, increased investments by top players in the region and the increasing acceptance of biosimilars and biologics are anticipated to fuel market expansion in the near future.

Key players in the market:

Some of the key players in Inflammatory Bowel Disease Treatment market include: Allergan plc., Janssen Biotech, Celltrion Inc., Pfizer Inc, Merck & co., inc, Bristol-myers squibb company, Bausch health companies inc, Takeda Pharmaceutical Company Limited, Novartis AG, UCB S.A., Amgen Inc, Johnson & Johnson Services, Inc, Biogen and AbbVie Inc.

Key Developments:

In October 2021, Bristol-Myers Squibb Company announced the approval of Zeposia (ozanimod) by the Committee for Medicinal Products for Human Use (CHMP) for the treatment of adults with moderately to severely active Ulcerative Colitis (UC).

In February 2021, the European Commission (EC) granted marketing authorization to CELLTRION INC.'s Yuflyma biosimilar used to treat adult and pediatric Crohn's disease and ulcerative colitis.

Types Covered:

  • Ulcerative Colitis
  • Crohn's Disease

Drug Class Covered:

  • JAK inhibitors
  • Anti-integrin
  • IL inhibitors
  • TNF inhibitors
  • Corticosteroids
  • Aminosalicylates
  • Other Drug Class

Route of Administrations Covered:

  • Injectable
  • Oral

Distribution Channels Covered:

  • Online Pharmacy
  • Retail Pharmacy
  • Hospital Pharmacy

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Inflammatory Bowel Disease Treatment Market, By Type

  • 5.1 Introduction
  • 5.2 Ulcerative Colitis
  • 5.3 Crohn's Disease

6 Global Inflammatory Bowel Disease Treatment Market, By Drug Class

  • 6.1 Introduction
  • 6.2 JAK inhibitors
  • 6.3 Anti-integrin
  • 6.4 IL inhibitors
  • 6.5 TNF inhibitors
  • 6.6 Corticosteroids
  • 6.7 Aminosalicylates
  • 6.8 Other Drug Class

7 Global Inflammatory Bowel Disease Treatment Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Injectable
  • 7.3 Oral

8 Global Inflammatory Bowel Disease Treatment Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Online Pharmacy
  • 8.3 Retail Pharmacy
  • 8.4 Hospital Pharmacy

9 Global Inflammatory Bowel Disease Treatment Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Allergan plc.
  • 11.2 Janssen Biotech
  • 11.3 Celltrion Inc.
  • 11.4 Pfizer Inc
  • 11.5 Merck & co., inc
  • 11.6 Bristol-myers squibb company
  • 11.7 Bausch health companies inc
  • 11.8 Takeda Pharmaceutical Company Limited
  • 11.9 Novartis AG
  • 11.10 UCB S.A.
  • 11.11 Amgen Inc
  • 11.12 Johnson & Johnson Services, Inc
  • 11.13 Biogen
  • 11.14 AbbVie Inc.,

List of Tables

  • Table 1 Global Inflammatory Bowel Disease Treatment Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Inflammatory Bowel Disease Treatment Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Inflammatory Bowel Disease Treatment Market Outlook, By Ulcerative Colitis (2021-2030) ($MN)
  • Table 4 Global Inflammatory Bowel Disease Treatment Market Outlook, By Crohn's Disease (2021-2030) ($MN)
  • Table 5 Global Inflammatory Bowel Disease Treatment Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 6 Global Inflammatory Bowel Disease Treatment Market Outlook, By JAK inhibitors (2021-2030) ($MN)
  • Table 7 Global Inflammatory Bowel Disease Treatment Market Outlook, By Anti-integrin (2021-2030) ($MN)
  • Table 8 Global Inflammatory Bowel Disease Treatment Market Outlook, By IL inhibitors (2021-2030) ($MN)
  • Table 9 Global Inflammatory Bowel Disease Treatment Market Outlook, By TNF inhibitors (2021-2030) ($MN)
  • Table 10 Global Inflammatory Bowel Disease Treatment Market Outlook, By Corticosteroids (2021-2030) ($MN)
  • Table 11 Global Inflammatory Bowel Disease Treatment Market Outlook, By Aminosalicylates (2021-2030) ($MN)
  • Table 12 Global Inflammatory Bowel Disease Treatment Market Outlook, By Other Drug Class (2021-2030) ($MN)
  • Table 13 Global Inflammatory Bowel Disease Treatment Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 14 Global Inflammatory Bowel Disease Treatment Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 15 Global Inflammatory Bowel Disease Treatment Market Outlook, By Oral (2021-2030) ($MN)
  • Table 16 Global Inflammatory Bowel Disease Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 17 Global Inflammatory Bowel Disease Treatment Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 18 Global Inflammatory Bowel Disease Treatment Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 19 Global Inflammatory Bowel Disease Treatment Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 20 North America Inflammatory Bowel Disease Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 21 North America Inflammatory Bowel Disease Treatment Market Outlook, By Type (2021-2030) ($MN)
  • Table 22 North America Inflammatory Bowel Disease Treatment Market Outlook, By Ulcerative Colitis (2021-2030) ($MN)
  • Table 23 North America Inflammatory Bowel Disease Treatment Market Outlook, By Crohn's Disease (2021-2030) ($MN)
  • Table 24 North America Inflammatory Bowel Disease Treatment Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 25 North America Inflammatory Bowel Disease Treatment Market Outlook, By JAK inhibitors (2021-2030) ($MN)
  • Table 26 North America Inflammatory Bowel Disease Treatment Market Outlook, By Anti-integrin (2021-2030) ($MN)
  • Table 27 North America Inflammatory Bowel Disease Treatment Market Outlook, By IL inhibitors (2021-2030) ($MN)
  • Table 28 North America Inflammatory Bowel Disease Treatment Market Outlook, By TNF inhibitors (2021-2030) ($MN)
  • Table 29 North America Inflammatory Bowel Disease Treatment Market Outlook, By Corticosteroids (2021-2030) ($MN)
  • Table 30 North America Inflammatory Bowel Disease Treatment Market Outlook, By Aminosalicylates (2021-2030) ($MN)
  • Table 31 North America Inflammatory Bowel Disease Treatment Market Outlook, By Other Drug Class (2021-2030) ($MN)
  • Table 32 North America Inflammatory Bowel Disease Treatment Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 33 North America Inflammatory Bowel Disease Treatment Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 34 North America Inflammatory Bowel Disease Treatment Market Outlook, By Oral (2021-2030) ($MN)
  • Table 35 North America Inflammatory Bowel Disease Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 36 North America Inflammatory Bowel Disease Treatment Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 37 North America Inflammatory Bowel Disease Treatment Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 38 North America Inflammatory Bowel Disease Treatment Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 39 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 40 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Type (2021-2030) ($MN)
  • Table 41 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Ulcerative Colitis (2021-2030) ($MN)
  • Table 42 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Crohn's Disease (2021-2030) ($MN)
  • Table 43 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 44 Europe Inflammatory Bowel Disease Treatment Market Outlook, By JAK inhibitors (2021-2030) ($MN)
  • Table 45 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Anti-integrin (2021-2030) ($MN)
  • Table 46 Europe Inflammatory Bowel Disease Treatment Market Outlook, By IL inhibitors (2021-2030) ($MN)
  • Table 47 Europe Inflammatory Bowel Disease Treatment Market Outlook, By TNF inhibitors (2021-2030) ($MN)
  • Table 48 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Corticosteroids (2021-2030) ($MN)
  • Table 49 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Aminosalicylates (2021-2030) ($MN)
  • Table 50 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Other Drug Class (2021-2030) ($MN)
  • Table 51 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 52 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 53 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Oral (2021-2030) ($MN)
  • Table 54 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 55 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 56 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 57 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 58 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 59 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Type (2021-2030) ($MN)
  • Table 60 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Ulcerative Colitis (2021-2030) ($MN)
  • Table 61 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Crohn's Disease (2021-2030) ($MN)
  • Table 62 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 63 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By JAK inhibitors (2021-2030) ($MN)
  • Table 64 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Anti-integrin (2021-2030) ($MN)
  • Table 65 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By IL inhibitors (2021-2030) ($MN)
  • Table 66 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By TNF inhibitors (2021-2030) ($MN)
  • Table 67 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Corticosteroids (2021-2030) ($MN)
  • Table 68 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Aminosalicylates (2021-2030) ($MN)
  • Table 69 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Other Drug Class (2021-2030) ($MN)
  • Table 70 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 71 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 72 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Oral (2021-2030) ($MN)
  • Table 73 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 74 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 75 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 76 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 77 South America Inflammatory Bowel Disease Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 78 South America Inflammatory Bowel Disease Treatment Market Outlook, By Type (2021-2030) ($MN)
  • Table 79 South America Inflammatory Bowel Disease Treatment Market Outlook, By Ulcerative Colitis (2021-2030) ($MN)
  • Table 80 South America Inflammatory Bowel Disease Treatment Market Outlook, By Crohn's Disease (2021-2030) ($MN)
  • Table 81 South America Inflammatory Bowel Disease Treatment Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 82 South America Inflammatory Bowel Disease Treatment Market Outlook, By JAK inhibitors (2021-2030) ($MN)
  • Table 83 South America Inflammatory Bowel Disease Treatment Market Outlook, By Anti-integrin (2021-2030) ($MN)
  • Table 84 South America Inflammatory Bowel Disease Treatment Market Outlook, By IL inhibitors (2021-2030) ($MN)
  • Table 85 South America Inflammatory Bowel Disease Treatment Market Outlook, By TNF inhibitors (2021-2030) ($MN)
  • Table 86 South America Inflammatory Bowel Disease Treatment Market Outlook, By Corticosteroids (2021-2030) ($MN)
  • Table 87 South America Inflammatory Bowel Disease Treatment Market Outlook, By Aminosalicylates (2021-2030) ($MN)
  • Table 88 South America Inflammatory Bowel Disease Treatment Market Outlook, By Other Drug Class (2021-2030) ($MN)
  • Table 89 South America Inflammatory Bowel Disease Treatment Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 90 South America Inflammatory Bowel Disease Treatment Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 91 South America Inflammatory Bowel Disease Treatment Market Outlook, By Oral (2021-2030) ($MN)
  • Table 92 South America Inflammatory Bowel Disease Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 93 South America Inflammatory Bowel Disease Treatment Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 94 South America Inflammatory Bowel Disease Treatment Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 95 South America Inflammatory Bowel Disease Treatment Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 96 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 97 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Type (2021-2030) ($MN)
  • Table 98 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Ulcerative Colitis (2021-2030) ($MN)
  • Table 99 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Crohn's Disease (2021-2030) ($MN)
  • Table 100 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 101 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By JAK inhibitors (2021-2030) ($MN)
  • Table 102 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Anti-integrin (2021-2030) ($MN)
  • Table 103 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By IL inhibitors (2021-2030) ($MN)
  • Table 104 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By TNF inhibitors (2021-2030) ($MN)
  • Table 105 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Corticosteroids (2021-2030) ($MN)
  • Table 106 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Aminosalicylates (2021-2030) ($MN)
  • Table 107 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Other Drug Class (2021-2030) ($MN)
  • Table 108 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 109 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Injectable (2021-2030) ($MN)
  • Table 110 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Oral (2021-2030) ($MN)
  • Table 111 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 112 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 113 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 114 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)